A method for determining the efficacy of GPC3-targeted therapeutics for cancer in a patient or patient prior to receiving GPC3-targeted therapeutics or for determining the continuation of GPC3-targeted therapeutics for a patient, comprising: Including monitoring free GPC3 levels in biological samples isolated from patients prior to receiving therapy and / or patients receiving GPC3-targeted therapeutics, where the free GPC3 level is a predetermined value Discloses a method for determining that the GPC3-targeted therapeutic is effective, or for determining the continuation of the GPC3-targeted therapeutic. Also disclosed are GPC3-targeted therapeutic agents or formulations for further administration to patients who have been determined that GPC3-targeted therapeutics are effective or who have decided to continue with GPC3-targeted therapeutics.
展开▼
